Public consultation on assessment criteria for combination packages policy by Dutch regulator

21 November 2016

The Netherlands Medicines Evaluation Board (MEB) is inviting interested parties and stakeholders to comment on the draft policy document on the assessment criteria for combination packages (MEB 47).

The proposed policy applies to human medicinal products. Comments can be made on the policy document via a public consultation until 30 December 2016.

Combination packages are packages which contain more than one medicinal product and are marketed under a single trade name and a single marketing authorization. The individual products are different as regards qualitative or quantitative composition and are administered simultaneously or sequentially.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK